Age-dependent metabolic effects of second-generation antipsychotics in second-generation Antipsychotic-naïve French Canadian patients

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 6, 2010, Pages 479-487

  Roy, Geneviève ^a   Bedard, Alain ^a   Desmarais, Paul André ^a   Jourdain, France ^a   Allen, Sylvie ^a   Michaud, Danielle ^a   Amor, Leila Ben ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGE; BODY MASS; BODY WEIGHT; CAUCASIAN; CHILD; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPID METABOLISM; LIPIDS; MALE; METABOLIC DISEASES; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 78650634183     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2010.0011     Document Type: Conference Paper

References (50)

1. Alessi-Severini S, Biscontri RG, Collins DM, Kozyrskyj A, Sareen J, Enns MW: Utilization and costs of antipsychotic agents: A Canadian population-based study, 1996-2006. Psychiatr Serv 59:547- 553, 2008.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
4. Ananth J, Kolli S, Gunatilake S, Brown S: Atypical antipsychotic drugs, diabetes and ethnicity. Expert Opin Drug Saf 4:1111-1124, 2005.
5. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J: Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 58:589-594, 2005a.
6. Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV: An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 15:311-317, 2005b. (Pubitemid 40734110)
7. Cascade E, Kalali A, Findling R: Use of antipsychotics in children. Psychiatry (Edgmont) 6:21-23, 2009.
8. Casey DE: Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 65 Suppl 18:27-35, 2004.
9. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Le-bovitz HE, Hennekens CH: Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65 Suppl 7:4-18; quiz 19-20, 2004.
10. Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, Gonzalez-Pinto A, Graell M, Paya B, Moreno D, de la Serna E, Arango C: Antipsychotic treatment in child and adolescent first-episode psychosis: A longitudinal naturalistic approach. J Child Adolesc Psy-chopharmacol 18:327-336, 2008.
11. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TM, De-Maso DR: A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 12:337-345, 2002.
12. Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 46:687-700, 2007.
13. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006.
14. Correll CU, Frederickson AM, Kane JM, Manu P: Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67:575-583, 2006.
15. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
16. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM: A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 68:789-795, 2007.
17. Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E, Mastele A, Wehmeier PM: Effectiveness and tolera-bility of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: Results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 18:54-69, 2008.
18. Domino ME, Swartz MS: Who are the new users of antipsychotic medications? Psychiatr Serv 59:507-514, 2008.
19. Fedorowicz VJ, Fombonne E: Metabolic side effects of atypical an-tipsychotics in children: A literature review. J Psychopharmacol 19:533-550, 2005.
20. Fraguas D, Merchan-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giraldez M, Arango C: Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69:1166-1175, 2008.
21. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM: A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11: 239-250, 2001.
22. Haddad PM, Sharma SG: Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 21:911-936, 2007.
23. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR: Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11:229-238, 2001.
24. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M: Management of psychiatric disorders in children and adolescents with atypical antipsychotics: A systematic review of published clinical trials. Eur Child Adolesc Psychiatry 16:104-120, 2007.
25. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ: Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 62 Suppl 2:41-44, 2001.
26. Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB, de Jong-van den Berg LT: Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 59:554-560, 2008.
27. Kapetanovic S, Aaron L, Montepiedra G, Sirois PA, Oleske JM, Malee K, Pearson DA, Nichols SL, Garvie PA, Farley J, Nozyce ML, Mintz M, Williams PL: The use of second-generation anti-psychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV. AIDS Patient Care STDS 23:939-947, 2009.
28. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD: Long-term olan-zapine treatment: Weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92-100, 2001.
29. Koller EA, Cross JT, Schneider B: Risperidone-associated diabetes mellitus in children. Pediatrics 113:421-422; author reply 421-422, 2004a.
30. Koller EA, Weber J, Doraiswamy PM, Schneider BS: A survey of reports of quetiapine-associated hyperglycemia and diabetes mel-litus. J Clin Psychiatry 65:857-863, 2004b.
31. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1-56, 2004.
32. Martin A, L'Ecuyer S: Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 11:129-133, 2002.
33. McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psycho-pharmacol 18:501-508, 2008.
34. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19 Suppl 1:1-93, 2005.
35. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL: Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naive population. Schizophr Res 99:13-22, 2008.
36. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337- 343, 2002.
37. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M: Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16:260-272, 2006.
38. Ross RG, Novins D, Farley GK, Adler LE: A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13:301-309, 2003.
39. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429-436, 2004.
40. Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, Gierow B, Maier J, Meyer E, Schulte-Markwort M: A prospective 12-week study of quetiapine in ado lescents with schizophrenia pectrum disorders. J Child Adolesc Psychopharmacol 17:768-778, 2007.
41. Schubert I, Lehmkuhl G: Increased antipsychotic prescribing to youths in Germany. Psychiatr Serv 60:269, 2009.
42. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415- 424, 2001.
43. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind com parison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431, 2008.
44. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsycho-pharmacology 29:133-145, 2004.
45. Simon V, van Winkel R, De Hert M: Are weight gain and metabolic side effects of atypical antipsychotics dose dependant? A literature review. J Clin Psychiatry 70:1041-1050, 2009.
46. Stigler KA, Potenza MN, Posey DJ, McDougle CJ: Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Paediatr Drugs 6: 33-44, 2004.
47. Toren P, Ratner S, Laor N, Weizman A: Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 27:1135- 1156, 2004.
48. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
49. Wetterling T: Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59-73, 2001.
50. Woods SW, Martin A, Spector SG, McGlashan TH: Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 41:1439-1446, 2002.